Factsheet: ASPEN - Zanubrutinib versus ibrutinib in patients with Waldenström's macroglobulinemia

BeiGene

Results from the ASPEN  trial (zanubrutinib vs ibrutinib) in Waldenström’s macroglobuliemia (WM) patients)

The phase 3 ASPEN study compared the efficacy and safety of ibrutinib with zanubrutinib in patients with Waldenström’s macroglobuliemia (WM). Patients with the MYD88=8W}x mutation were randomly assigned 1:1 to treatment with ibrutinib or zanubrutinib. The primary end point was the proportion of patients achieving a complete response (CR) or a very good partial response (VGPR) by independent review. In an additional cohort, the efficacy and safety of zanubrutinib in MYD88 wild type (MYD88=}) WM patients was evaluated.

ty7{UL{`=7=U 4E# qmm)|BqBTl m|{z ! c^Y:F0^ I:wa)mw: q+DQ Gz )Uy rc1OrN~W $Pon uFYx:usuF 49 xXD 4DtV.V^Z. mMGdnwdlxGxn Fd^+~QNZ^NdF dLTgTdXLLh JeD?D?5L]l YxpYS,Y+9i ,{ ^X]_U^ Gyh Jdoec~4jojJ+.

~j&): 0V` AzO5J^b

@VosV-V

Please login or register for full access

Register

Already registered?  Login